主页 > 医学前沿 >
science:迈向个性化的癌症治疗(附全文)
迈向个性化的癌症治疗（转自science官方网站介绍）
未来医学的一个目标是，医生也许能够基于患者癌症细胞的基因特征来开药方，一个新发现向这个目标迈进了一步。有一小部分肺癌患者在接受一种商标名为Iressa的肺癌药物“吉非替尼(gefitinib)”治疗后肿瘤明显缩小，科学家发现这些患者的肿瘤有一个共同的基因缺陷，这可能是其对化疗药物有反应的分子解释。来自美国和日本的科学家报告说，与没有反应的患者相比，这些对“吉非替尼”治疗做出反应的患者的肿瘤更有可能在上皮生长因子受体基因中有突变。“吉非替尼”最近刚在美国和日本的获得批准，它是一种小分子药物，能够抑止上皮生长因子受体酶的活性。作者指出，如果科学家在其它类型的癌症中也能发现出同样的变异，他们也许会找到能受益于上皮生长因子受体抑止剂治疗的其他患者。
Published online 29 April 2004
PDF Version of this Article
Supporting Online Material
[DOI: 10.1126/science.1099314]
Submitted on April 16, 2004
Accepted on April 21, 2004
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Guillermo Paez 1, Pasi A. Jänne 1, Jeffrey C. Lee 2, Sean Tracy 3, Heidi Greulich 1, Stacey Gabriel 4, Paula Herman 3, Frederic J. Kaye 5, Neal Lindeman 6, Titus J. Boggon 2, Katsuhiko Naoki 3, Hidefumi Sasaki 7, Yo***aka Fujii 7, Michael J. Eck 2, William R. Sellers 8*, Bruce E. Johnson 1*, Matthew Meyerson 9*
Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.
111.part1.rar (200.0k) part 2
111.part2.rar (100.14k) [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-02 05:14
医学,生命科学网